Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
-
Vermersch, Patrick
Neurology, University of Lille Nord de France, Lille, France
-
Czlonkowska, Anna
Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
-
Grimaldi, Luigi ME
Fondazione Istituto San Raffaele “G. Giglio” di Cefalù, Cefalù, Italy
-
Confavreux, Christian
Neurology, University Claude Bernard, Lyon, France
-
Comi, Giancarlo
Neurology and Neurophysiology, University Vita-Salute San Raffaele, Milan, Italy
-
Kappos, Ludwig
Neurology and Department of Biomedicine, University Hospital Basel, Basel, Switzerland
-
Olsson, Tomas P
Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
-
Benamor, Myriam
Global Pharmacovigilance and Epidemiology, Sanofi, Chilly Mazarin, France
-
Bauer, Deborah
Statistics, Sanofi, Bridgewater, NJ, USA
-
Truffinet, Philippe
Global Pharmacovigilance and Epidemiology, Sanofi, Chilly Mazarin, France
-
Church, Meg
Neurology, Fishawack Communications Ltd, North Wales, PA, USA
-
Miller, Aaron E
Corinne Goldsmith Dickinson Centre of Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA
-
Wolinsky, Jerry S
Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA
-
Freedman, Mark S
University of Ottawa, the Ottawa Hospital Research Institute, Ottawa, ON, Canada
-
O’Connor, Paul
St Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, ON, Canada
Show more…
Published in:
- Multiple Sclerosis Journal. - SAGE Publications. - 2013, vol. 20, no. 6, p. 705-716
English
Background: In previous studies, teriflunomide significantly reduced the annualised relapse rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study (NCT00883337) compared teriflunomide with interferon-beta-1a (IFNβ-1a). Methods: Patients with relapsing multiple sclerosis were randomised (1:1:1) to oral teriflunomide 7-or 14mg, or subcutaneous IFNβ-1a 44µg. The primary composite endpoint was time to failure, defined as first occurrence of confirmed relapse or permanent treatment discontinuation for any cause. Secondary endpoints included ARR, Fatigue Impact Scale (FIS) and Treatment Satisfaction Questionnaire for Medication (TSQM). The study was completed 48 weeks after the last patient was randomised. Results: Some 324 patients were randomised (IFNβ-1a: 104; teriflunomide 7 mg: 109; teriflunomide 14 mg: 111). No difference in time to failure was observed. There was no difference in ARR between teriflunomide 14 mg and IFNβ-1a, but ARR was significantly higher with teriflunomide 7 mg. FIS scores indicated more frequent fatigue with IFNβ-1a, though differences were only significant with teriflunomide 7 mg. TSQM scores were significantly higher with teriflunomide. There were no unexpected safety findings. Conclusion: Effects on time to failure were comparable between teriflunomide and IFNβ-1a. There was no difference between teriflunomide 14 mg and IFNβ-1a on ARR, though ARR was higher with teriflunomide 7 mg. The teriflunomide safety profile was consistent with previous studies.
-
Language
-
-
Open access status
-
hybrid
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/201616
Statistics
Document views: 20
File downloads: